Inhibrx Biosciences (INBX) CEO Lappe Mark Buys $849K of Stock

Mark Lappe, the Chief Executive Officer of Inhibrx Biosciences, Inc. (NasdaqGS: INBX), purchased 10,040 shares on October 14, 2026. The transaction, valued at about $848,976, occurred at an average price of $84.56 per share. This move reflects Lappe's confidence in the company's prospects as it continues to develop biologic therapeutics for serious conditions.

Inside Lappe's Trade

Lappe's recent buy adds to his considerable stake in Inhibrx, emphasizing his belief in the company's future. Following this purchase, it remains to be seen how other insiders might respond, especially given the recent volatility in the stock's price. The shares are currently trading at $87.91, which is substantially below the 52-week high of $155.29.

Other Institutional Activity in Inhibrx

Several institutional investors have held or adjusted their positions in Inhibrx recently. Morgan Stanley owns 1,308,051 shares, after increasing its stake by 44,966 shares. Perceptive Advisors, however, reduced its holdings by 144,997 shares, bringing its total to 1,297,763 shares. Sanofi maintained its position with 1,157,926 shares, and Viking Global Investors cut its stake by 313,688 shares to 1,123,929 shares. HighTower Advisors added a modest 348 shares, ending with 870,551 shares. These moves illustrate varying levels of confidence among institutions.

Inhibrx Biosciences, Inc. Stock Down 19.6%

Inhibrx's stock is currently at $87.91, trading well below its 200-day moving average of $90.33. This could indicate an opportunity for investors as the company navigates its clinical-stage pipeline. The market capitalization stands at approximately $1.65 billion. The shares have fluctuated significantly over the past year, with a 52-week low of $27.12.

Recent Earnings

Inhibrx has yet to report any earnings since it has not reached profitability, reflecting its clinical-stage status. The next earnings report is scheduled for November 13, 2026. This upcoming announcement will be crucial for investors looking for insights into the company's financial health and operational progress.

Insider Buying and Selling at Inhibrx Biosciences, Inc.

Lappe has been active in the market, having purchased 10,040 shares on October 14, 2026. This follows another buy of 10,000 shares on September 28, 2026. Additionally, Jon Faiz Kayyem, a Director, also made two purchases of 5,000 shares each on September 16 and 23, 2026, at an average price of $100 per share. These insider activities suggest a strong belief in the company's direction and potential growth.

Analysts Set New Price Targets

On August 24, 2026, HC Wainwright & Co. initiated coverage on Inhibrx with a Buy rating and set a price target of $245.00. The consensus recommends a strong buy with an average target of $266.67 based on three analyst opinions. This positive outlook may bolster investor confidence moving forward.

About Inhibrx Biosciences

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California. The company specializes in creating biologic therapeutics aimed at treating life-threatening conditions. With a growing focus on innovative solutions, Inhibrx continues to attract interest from both investors and analysts alike.

Bottom Line

Mark Lappe's recent share purchase adds another layer of optimism to Inhibrx's narrative as it approaches its upcoming earnings report. The company's stock, while currently trading below its potential, has analysts bullish on its long-term prospects. Investors should keep an eye on further insider trades and the next earnings announcement for more insights.